Alvotech announces australian marketing authorization for avt02, a biosimilar to humira®

Reykjavik, iceland and mumbai, india (november 14, 2022) - alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today that the therapeutic goods administration of australia has granted marketing authorization to cipla australia pty ltd (“cipla”) for alvotech's avt02, a high-concentration low-volume biosimilar to humira® (adalimumab).
ALVO Ratings Summary
ALVO Quant Ranking